Optic Neuritis News and Research

RSS

Optic neuritis is a condition in which the optic nerve becomes inflamed and swollen, leading to an acute severe impairment of vision in the affected eye. The swelling may further lead to damage to the nerve fibers running through the nerve, causing permanent or temporary loss of vision in that eye. It is much more common in young female patients.

FDA approves expanded use of systemic therapy for treating chronic moderate-to-severe pediatric psoriasis

Amgen today announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for the expanded use of ENBREL (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis.

7 Nov 2016

Color-deficiency or color-blindness?

Color blindness could be considered a bit of a misleading term, because there are very few people who can't see color at all. Most people have what we call color deficiency or color confusion, which means that they're not blind to color; they just see a reduced number of colors.

From Vision Express 22 Sep 2016

Common antihistamine may partially reverse damage to visual system in multiple sclerosis patients

A common antihistamine used to treat symptoms of allergies and the common cold, called clemastine fumarate, partially reversed damage to the visual system in people with multiple sclerosis (MS) in a preliminary study released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.

13 Apr 2016

Retinal thickness points to disability worsening in MS patients

The thickness of the peripapillary retinal nerve fibre layer (pRNFL) may help to predict worsening disability in patients with multiple sclerosis (MS), optical coherence tomography (OCT) ...

24 Mar 2016

Taste deficits appear to be more prevalent in MS patients

Taste deficits appear to be more prevalent among multiple sclerosis (MS) patients than previously reported and correlate with brain lesions left by the debilitating disease, a new study from the University of Pennsylvania's Smell and Taste Center and the department of Radiology found.

9 Feb 2016

Neuroprotection powers for phenytoin in acute optic neuritis

Selective sodium channel blockade with the anti-epileptic drug phenytoin protects against acute demyelinating optic neuritis, researchers report.

29 Jan 2016

Escalation therapy for neuromyelitis attacks improves remission rates

Researchers recommend escalating patients’ therapy in the event of continuing attacks of neuromyelitis optica, basing sequential treatment on the type of attack and prior treatment response.

16 Nov 2015

Multiple sclerosis relapse management: an interview with Gina Remington

MS relapses are typically reflective of new neurological symptoms. However, it can be a worsening of neurologic symptoms that begins after a patient has been stable (generally for about 30 days), but relapses are persistent and consistent changes in symptoms that occur for more than 24 to 48 hours.

26 Jul 2015

Children recover well from acute central nervous system demyelination

Most children can expect a good and quick physical recovery following acute central nervous system demyelination, study findings suggest.

20 Jul 2015

International consensus panel reviews new diagnostic criteria for neuromyelitis optica spectrum disorder

New diagnostic criteria were introduced this week for neuromyelitis optica, now called neuromyelitis optica spectrum disorder, which is an inflammatory disease of the central nervous system that is sometimes mistaken for multiple sclerosis.

9 Jul 2015

MedDay announces additional positive results from MD1003 Phase III trial in patients with progressive MS

MedDay, a biotechnology company focused on the treatment of nervous system disorders, reports additional positive data from its pivotal Phase III clinical trial, MS-SPI, with MD1003, a highly-concentrated pharmaceutical grade biotin, in patients with Progressive Multiple Sclerosis.

19 Jun 2015

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck, known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

1 Jun 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19.

17 May 2015

Two existing drugs may reverse damage caused by multiple sclerosis

A pair of topical medicines already alleviating skin conditions each may prove to have another, even more compelling use: instructing stem cells in the brain to reverse damage caused by multiple sclerosis.

21 Apr 2015

Study shows epilepsy drug can protect vision of MS patients

A drug commonly taken to prevent seizures in epilepsy may surprisingly protect the eyesight of people with multiple sclerosis (MS), according to a study released today that will be presented at the American Academy of Neurology's 67th Annual Meeting in Washington, DC, April 18 to 25, 2015.

17 Apr 2015

Quadrivalent HPV vaccine cleared of multiple sclerosis risk

A study of almost 4 million girls and women allays fears that receipt of the quadrivalent human papillomavirus vaccine could increase the risk of developing multiple sclerosis, or other demyelinating disorders.

7 Jan 2015

Yoga program for MS patients improves physical and mental well-being

Paula Meltzer was only 38 when out of nowhere everything she looked at was blurry. For the single mother, who had a lucrative career as a gemologist and spent hours examining valuable pieces of jewelry, it seemed as if - in a split second - her life changed.

3 Sep 2014

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology.

3 Jul 2014

Caregivers selected to receive the 2013 Shire BRAVE Awards

Selflessness, determination, courage and hope. These are among the qualities that describe the eighteen caregivers from around the world who have been selected as recipients of the 2013 Shire BRAVE Awards, an international program that honors the bravery and devotion of non-professional carers.

27 Nov 2013

Glaucoma and cell death: an interview with Dr. Vivek Gupta

Glaucoma is normally caused by increased pressure of aqueous humour fluid in the eye. A defining feature of this disease is destruction of a particular type of cells in the retina called retinal ganglion cells and excavation of the optic disc region.

31 Aug 2012